Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialPaolo A. Ascierto, James Larkin, Grant A. McArthur et al.|The Lancet Oncology|2016Cited by 1k
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisJennifer L. McQuade, Michael A. Davies, Mathilde Kaper et al.|The Lancet Oncology|2018Cited by 658
5-Year Outcomes with Cobimetinib plus Vemurafenib in <i>BRAF</i> V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM StudyPaolo A. Ascierto, Grant A. McArthur, Brigitte Dréno et al.|Clinical Cancer Research|2021Cited by 182
Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with <i>BRAF</i><sup>V600</sup> mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.Brigitte Dréno, James Larkin, Paolo A. Ascierto et al.|Journal of Clinical Oncology|2018Cited by 27
25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM studyGrant A. McArthur, A. Ribas, James Larkin et al.|European Journal of Cancer|2015Cited by 10